In:
Tumori Journal, SAGE Publications, Vol. 89, No. 5 ( 2003-09), p. 492-496
Abstract:
Hematological and extra-hematological toxicity of mitoxantrone-containing regimens with autologous stem cell rescue was evaluated in 32 metastatic breast cancer patients. The schedule was the final part of two high-dose chemotherapy programs, including an induction phase with three courses of conventional chemotherapy with epirubicin (120 mg/m 2 ) and cyclophosphamide (600 mg/m 2 ) plus three courses of docetaxel (100 mg/m 2 ) and a first high-dose chemotherapy consisting of cyclophosphamide (6000 mg/m 2 ), thiotepa (500 mg/m 2 ) and carboplatin (800 mg/m 2 ) or melphalan (160 mg/m 2 ) plus thiotepa (600 mg/m 2 ). The final second autograft phase included mitoxantrone (60 mg/m 2 ) associated with melphalan (160 mg/m 2 ) and autologous stem cell rescue infusion. The median duration of severe neutropenia and thrombocytopenia was 9 (range, 7–13) and 11.5 (range, 9–29) days. The median number of units of erythrocytes and platelets transfused was 1 (0–11) and 4 (1–9), respectively. Fever for a median of 2 (0–8) days developed in 71.8% of the patients. Mucositis was observed in 81.2% (WHO grade 3–4 in 25%). No acute or late cardiac toxicity was observed. One patient died because of a transplant-unrelated cause. The response according to the program phase showed an increased rate of complete response, from 12.5% at the end of conventional chemotherapy to 21.9% after the first high-dose chemotherapy course, to increase to 43.9% after the treatment with mitoxantrone-melphalan. We conclude that a conditioning regimen with high dose mitoxantrone-melphalan fits well within the high-dose chemotherapy program.
Type of Medium:
Online Resource
ISSN:
0300-8916
,
2038-2529
DOI:
10.1177/030089160308900506
Language:
English
Publisher:
SAGE Publications
Publication Date:
2003
detail.hit.zdb_id:
280962-X
detail.hit.zdb_id:
2267832-3
Permalink